Cytokine therapy response as a selection criterion for cytoreductive nephrectomy in metastatic renal clear-cell carcinoma of intermediate prognosis: Results and conclusions from a combined analysis

Urologia Internationalis

Volumn 80, Issue 4, 2008, Pages 367-371

  Bex, Axel ^a   Haanen, John B A G ^a   Vyth Dreese, Florry A ^a   Horenblas, Simon ^a   De Gast, Gijsbert C ^a  

^a NETHERLANDS CANCER INSTITUTE   (Netherlands)

Author keywords

Cytokines; Metastasis; Nephrectomy; Renal cell carcinoma

Indexed keywords

ALPHA INTERFERON; ALPHA2B INTERFERON; CYTOKINE; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; INTERLEUKIN 2;

ADULT; AGED; ARTICLE; CANCER IMMUNOTHERAPY; CANCER STAGING; CANCER SURVIVAL; CLASSIFICATION; CLEAR CELL CARCINOMA; CLINICAL ARTICLE; CLINICAL TRIAL; DRUG DOSE INCREASE; DRUG EFFECT; DRUG EFFICACY; DRUG RESPONSE; FEMALE; HUMAN; KIDNEY CARCINOMA; MALE; MEMORIAL SLOAN KETTERING PROGNOSTIC INDEX CLASSIFICATION; METASTASIS; NEPHRECTOMY; OUTCOME ASSESSMENT; PATIENT SELECTION; PRIORITY JOURNAL; PROGNOSIS; RETROSPECTIVE STUDY; SURVIVAL TIME; TREATMENT INDICATION; TREATMENT OUTCOME;

ADULT; AGED; CARCINOMA, RENAL CELL; COMBINED MODALITY THERAPY; CONFIDENCE INTERVALS; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; INJECTIONS, SUBCUTANEOUS; INTERFERON ALFA-2B; INTERFERON-ALPHA; KIDNEY NEOPLASMS; LYMPHATIC METASTASIS; MALE; MIDDLE AGED; NEOPLASM INVASIVENESS; NEOPLASM STAGING; NEPHRECTOMY; PATIENT SELECTION; PROBABILITY; PROGNOSIS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RETROSPECTIVE STUDIES; RISK ASSESSMENT; SURVIVAL ANALYSIS; TIME FACTORS; TREATMENT OUTCOME;

EID: 46249083305     PISSN: 00421138     EISSN: None     Source Type: Journal    
DOI: 10.1159/000132693     Document Type: Article

References (18)

1. Flanigan RC, Salmon SE, Blumenstein BA, et al: Nephrectomy followed by interferon alfa-2b compared with interferon alfa-2b alone for metastatic renal-cell carcinoma. N Engl J Med 2001;345:1655-1659.
2. Mickisch GH, Garin A, van Poppel H, de Prijck L, Sylvester R: Radical nephrectomy plus interferon-alfa-based immunotherapy compared with interferon alfa alone in metastatic renal-cell carcinoma: a randomised trial. Lancet 2001;358:966-970.
3. Motzer RJ, Bacik J, Murphy BA, Russo P, Mazumdar M: Interferon-alfa as a comparative treatment for clinical trials of new therapies against advanced renal cell carcinoma. J Clin Oncol 2002;20:289-296.
4. Patard JJ, Kim HL, Lam JS, et al: Use of the University of California Los Angeles Integrated Staging System to predict survival in renal cell carcinoma: an international multicenter study. J Clin Oncol 2004;22:3316-3322.
5. Bex A, Horenblas S, Meinhardt W, Verra NC, de Gast GC: The role of initial immunotherapy as selection for nephrectomy in patients with metastatic renal cell carcinoma and the primary in situ. Eur Urol 2002;42:570-576.
6. Bex A, Kerst JM, Mallo H, Meinhardt W, Horenblas S, de Gast GC: Interferon alfa 2b as medical selection for nephrectomy in patients with synchronous metastatic renal cell carcinoma: a consecutive study. Eur Urol 2006;49:76-81.
7. Motzer RJ, Bacik J, Mazumdar M: Prognostic factors for survival of patients with stage IV renal cell carcinoma: Memorial Sloan-Kettering Cancer Center experience. Clin Cancer Res 2004;10(suppl):6302s-6303s.
8. Therasse P, Arbuck SG, Eisenhauer EA, et al: New guidelines to evaluate the response to treatment in solid tumors. J Natl Cancer Inst 2000;92:205-216.
9. de Gast GC, Klumpen HJ, Vyth-Dreese FA, et al: Phase I trial of combined immunotherapy with subcutaneous granulocyte macrophage colony-stimulating factor, low-dose interleukin 2, and interferon alpha in progressive metastatic melanoma and renal cell carcinoma. Clin Cancer Res 2002;4:1267-1272.
10. Freed SZ: Nephrectomy for renal cell carcinoma with metastases. Urology 1977;9:613-616.
11. deKernion J, Ramming KP, Smith RB: The natural history of metastatic renal cell carcinoma: a computer analysis. J Urol 1978;120:148-152.
12. Neves RJ, Zincke H, Taylor WF: Metastatic renal cell cancer and radical nephrectomy: identification of prognostic factors and patient survival. J Urol 1988;139:1173-1176.
13. Rackley R, Novick A, Klein E, Bukowski R, McLain D, Goldfarb D: The impact of adjuvant nephrectomy on multimodality treatment of metastatic renal cell carcinoma. J Urol 1994;152:1399-1403.
14. Bennet RT, Lerner SE, Taub HC, Dutcher JP, Fleischmann J: Cytoreductive surgery for stage IV renal cell carcinoma. J Urol 1995;154:32-34.
15. Flanigan RC: Cytoreductive nephrectomy in metastatic renal cell cancer. Curr Urol Rep 2003;4:36-40.
16. Pantuck AJ, Zisman A, Dorey F, et al: Renal cell carcinoma with retroperitoneal lymph nodes: impact on survival and benefits of immunotherapy. Cancer 2003;97:2995-3002.
17. Rini BI: VEGF-targeted therapy in metastatic renal cell carcinoma. Oncologist 2005;10:191-197.
18. Motzer RJ, Michaelson MD, Redman BG, et al: Activity of SU11248, a multitargeted inhibitor of vascular endothelial growth factor receptor and platelet-derived growth factor receptor, in patients with metastatic renal cell carcinoma. J Clin Oncol 2006;24:16-24.